Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenomics to Predict Responses to SGLT2 Inhibitors
NCT02891954Phase 1Active, not recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Sep 2016
- Primary completion
- Sep 2023
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of canagliflozin in type 2 diabetes mellitus (T2DM), sponsored by University of Maryland, Baltimore. Primary endpoint: Urinary glucose excretion. Started Sep 2016; status: active, not recruiting.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02891954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02891954.